Navigation Links
FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
Date:7/23/2009

e to 18 months of treatment by 7.2 percent at the lumbar spine, 3.6 percent at the total hip, and 3.7 percent at the femoral neck.(5)

"Until now, physicians and patients had only one class of approved therapy for the treatment of glucocorticoid-induced osteoporosis," said Kenneth G. Saag, M.D., MSc, professor of medicine and epidemiology at the University of Alabama in Birmingham. "The approval of teriparatide for this new indication offers healthcare providers and patients a new treatment option that effectively increases bone mineral density in a different way than anti-resorptives."

Label Updates

Since this new indication extends the use of FORTEO to patients with GIO who may be younger than those currently receiving the medication, Lilly has updated the language in the existing boxed warning section of the label regarding the risk of osteosarcoma to reinforce that FORTEO should not be used in pediatric and young adult patients whose bones are still growing.

In addition, due to the increased patient population, Lilly established a voluntary FORTEO Patient Registry to further evaluate the long-term safety of FORTEO. Osteosarcoma is a serious but rare cancer which occurs at a rate of about four cases per million people, per year. Osteosarcoma has been reported rarely in people who took FORTEO. It is not known if people who take FORTEO have a higher chance of getting osteosarcoma.

About FORTEO

FORTEO is also indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.(6) FORTEO is the first osteoporosis therapy approved by the U.S. Food and Drug Administration (FDA) that actually rebuilds bone.(7) Since receiving FDA approval in November 2002, more than 3.1 million prescriptions for FORTEO have been
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. American Academy of Orthopaedic Surgeons approves new guideline for the treatment of pediatric diaphyseal femur fractures
2. American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures
3. FDA Approves VITROS(R) Anti-HCV Assay for Use On VITROS 5600(R) Integrated and VITROS 3600(R) Immunodiagnostic Systems
4. FDA Approves Seasonal Flu Vaccine for 2009-2010
5. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
6. FDA Approves NovoLog(R) Labeling Update
7. Fitness Management Group, Inc. Approves Sale of the Company
8. Cardinal Health Board of Directors Approves CareFusion Spinoff
9. Video: FDA Approves Hologics Adiana(R) Permanent Contraception System
10. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
11. FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each ... among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and ... year, that process led the magazine to tap the National League for Nursing’s ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Symposium (WFS), cosponsored by the Military Officers Association of America (MOAA) and ... "Our Nation's Military: Caring For Our Own,” expert panelists will lead interactive ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... (blinatumomab) – in the news recently following a decision by the Centers for ... – is likely to average approximately $71,000 or roughly 40% of its headline-grabbing ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... pregnant, but visiting a behavioural therapist for a few ... ,Emory University gynaecologist Sarah Berga examined the value ... had stopped ovulating. ,When presenting her findings ... study of 16 women was small and that a ...
... this year in Assam, state Health Minister Himanta Biswa Sarma ... cut motions in the state assembly, Sarma said the exact ... not reached the state capital., ,Admitting that last year ... per cent of the affected area has been covered., ...
... affairs, China today nominated Hong Kong's Margaret Chan to ... Organisation (WHO).// ,Chan currently serves as WHO ... Director- General will be in November this year., ... Jong-wook from South Korea in May this year., ...
... to be infected with a strain of bird flu that may ... Ministry official// Yukol Limlaemthong on Monday. ,Yukol said, "There ... the area has had outbreaks before." ,Officials have ... was in the northern province of Pichit. This was one of ...
... on the heels of banning illegal organ transplants, China ... panacea for a range of blood disorders. ... Ministry of Health said that the sources of peripheral ... registered sources that can be traced., ,The regulations ...
... China's health insurance companies will offer a special policy for ... policy will be available from August 8 after the insurance ... ,It will be valid for 30 days and ... cost 88 yuan ($11) and compensation will include 10,000 yuan ...
Cached Medicine News:Health News:Stress Therapy can Restore Fertility: Study 2
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced the ... - November 19-20, 2015)" conference to their offering. ... industry case studies, regulatory updates, latest therapies and technology ... Steven Nichols , OINP Specialist Consultant and Mike ... participating include: - Aptar Pharma ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the ... - November 16-18, 2015)" conference to their offering. Regulatory ... including Columbia, Peru , Brazil , ... Uruguay , Paraguay , Venezuela ... Chile This seminar can be viewed ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
Store microscope slides with ease, speed, efficiency....
... drawers for just about everything imaginable that might ... Each box is designed for long term storage ... of wood over metal systems is overlooked, while ... subtle kind of desiccator and insulator, providing an ...
A prepared Microscope Slide Cataloging and Storage System....
... resistant, plastic covered corrugated boxes interlock ... up to 500 lbs of overhead ... accommodates 2000 slides or 500 tissue ... requirements. Come unassembled boxes require minimal ...
Medicine Products: